News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search


PHARMAC agrees funding for brain tumour treatment

Media release

PHARMAC agrees funding for brain tumour treatment

A new treatment for people with an aggressive form of brain tumour is to become fully subsidised from 1 May 2006.

Funding for temozolomide (Temodal) has been approved by PHARMAC for patients who are undergoing radiotherapy, and for a further six cycles of treatment following radiotherapy. Funding will be for newly diagnosed patients, and for those patients who may have already commenced treatment before 1 May 2006, and is anticipated to cost $6.5 million over five years.

About 100 patients per year are expected to receive funded access.

PHARMAC Medical Director Dr Peter Moodie says for those patients diagnosed with glioblastoma multiforme, the most aggressive form of brain tumour, temozolomide offers a beneficial treatment that can extend their life expectancy.

“The evidence shows that this is a treatment that can extend life, and we are pleased to be able to fund it,” Dr Moodie says.

“PHARMAC and its expert clinical committees looked very carefully at the evidence. It shows that temozolomide can make a difference for patients who have temozolomide with radiotherapy in the early stages after diagnosis, and this is why it is those patients who will receive funding.”

Though analysis shows that temozolomide is less cost-effective than some other medicines PHARMAC is looking at funding, the listing is justified on other grounds such as the limited treatment options for brain tumour patients.

Funding does not extend to patients with relapsed glioblastomas, however PHARMAC remains open to the possibility of funding temozolomide for relapsed patients should new evidence become available.

Dr Moodie acknowledged the co-operation of temozolomide’s supplier Schering-Plough, which had worked constructively with PHARMAC to move quickly through the application, assessment and subsidy process.


© Scoop Media

Culture Headlines | Health Headlines | Education Headlines


NZ On Air TV Funding: More Comedy Comes Out Of The Shadows

Paranormal Event Response Unit is a series conceived by Jemaine Clement and Taika Waititi as a TV spin-off from their highly acclaimed feature film What We Do In The Shadows. More>>


Mars News: Winners Announced For The 2016 Apra Silver Scroll Awards

Wellington singer-songwriter and internationally acclaimed musician Thomas Oliver has won the 2016 APRA Silver Scroll Award with his captivating love song ‘If I Move To Mars’. More>>


Scoop Review Of Books: Salt River Songs by Sam Hunt

Colin Hogg, a longtime comrade of Sam, writes in his Introduction that, ‘There is a lot of death in this collection of new poems by my friend Sam Hunt. It’s easier to count the poems here that don’t deal with the great destroyer than it is to point to the ones that do.’ More>>

Electronica: Restoring The World’s First Recorded Computer Music

University of Canterbury Distinguished Professor Jack Copeland and UC alumni and composer Jason Long have restored the earliest known recording of computer-generated music, created more than 65 years ago using programming techniques devised by Alan Turing. More>>


Scoop Review Of Books: Almost Getting Away With Murder

The Black Widow by Lee-Anne Cartier: Lee-Anne Cartier is the sister of the Christchurch man found to have been murdered by his wife, Helen Milner, after an initial assumption by police that his death, in 2009, was suicide. More>>

Howard Davis: Triple Echo - The Malevich/Reinhardt/Hotere Nexus

Howard Davis: The current juxtaposition of works by Ralph Hotere and Ad Reinhardt at Te Papa perfectly exemplifies Jean Michel Massing's preoccupation with the transmigration of imagery in a remarkable triple echo effect... More>>

Get More From Scoop



Search Scoop  
Powered by Vodafone
NZ independent news